MasTec secures $700 million term loan to fund acquisition
Get Alerts MTZ Hot Sheet
Join SI Premium – FREE
MasTec, Inc. (NYSE: MTZ) entered into a senior unsecured delayed draw term loan agreement on July 7, 2026, providing $700 million in commitments to help finance an unspecified acquisition.
The agreement, made with Bank of America, N.A. as administrative agent, is structured in two tranches: a $400 million three-year tranche and a $300 million four-year tranche. Both tranches are tied to the closing date of the acquisition and will be automatically terminated if the acquisition does not close.
The three-year tranche carries no amortization requirement, while the four-year tranche is subject to quarterly principal payments beginning after the first full fiscal quarter following the one-year anniversary of the closing date, starting at 5% per annum and increasing to 10% per annum after the third-year anniversary.
Interest rates on the loans are based on Term SOFR or a base rate, at the company's option. For the three-year tranche, the Term SOFR margin ranges from 1.000% to 1.500%. For the four-year tranche, the margin ranges from 1.125% to 1.625%. Margins are determined by MasTec's consolidated leverage ratio and debt rating. Undrawn commitments are subject to a ticking fee of 0.175%, beginning 60 days after the agreement's effective date.
The loans are unsecured and carry no guarantee from MasTec subsidiaries. The agreement requires MasTec to maintain a consolidated leverage ratio of no more than 3.50:1.00, with a temporary increase to 4.00:1.00 permitted in connection with qualifying acquisitions exceeding $200 million.
The agreement includes cross-default provisions with MasTec's other significant debt instruments and customary restrictions on acquisitions, mergers, debt incurrence, and asset sales.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MasTec (MTZ) PT Raised to $518 at Guggenheim
- SpaceX (SPCX) Is Turning Away Commercial Falcon Customers Beyond 2028 - Bloomberg
- Utah Medical Products (UTMD) Tops Q2 EPS by 84c
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Definitive Agreement, Maynard Um, Mark Zuckerberg, BofA/Merrill Lynch, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share